Dyne Therapeutics’ (DYN) Buy Rating Reiterated at Chardan Capital
Chardan Capital reaffirmed their buy rating on shares of Dyne Therapeutics (NASDAQ:DYN – Free Report) in a report issued on Friday,Benzinga reports. They currently have a $50.00 target price on the stock. A number of other research firms have also issued reports on DYN. Guggenheim reaffirmed a “buy” rating on shares of Dyne Therapeutics in […]
Chardan Capital reaffirmed their buy rating on shares of Dyne Therapeutics (NASDAQ:DYN – Free Report) in a report issued on Friday,Benzinga reports. They currently have a $50.00 target price on the stock. A number of other research firms have also issued reports on DYN. Guggenheim reaffirmed a “buy” rating on shares of Dyne Therapeutics in […]
